Elina Koustoumpardi is a panelist during the session titled “Hot Topics in Merger Control: Health Value Chain (Pharma, Healthcare), Sustainability, Innovation Defense.”
The panelists will explore the latest trends in pharmaceutical mergers, including the surge in AI-related deals in the sector and the updates on significant transactions like the Novo Holdings acquisition. The discussion will also delve into new theories of harm emerging in the pharma and healthcare sectors, including the Finnish Competition Authority’s push for more effective tools to address harmful concentrations and the Hellenic Competition Commission’s ongoing sector inquiry. Key decisions like the CVC/Ethinki Asfalistiki merger and the recent US court dismissal of the FTC’s lawsuit over healthcare roll-ups will be discussed, as well as the growing importance of sustainability in merger control, examining how sustainability concerns are shaping market definitions, theories of harm, and innovation defense.
For more information on this event, click here.
